Table 4. Earliest presence of psychotic symptoms and the corresponding RBC folate levels and medication/supplement data for each MTHFR C677T genotype.
| MTHFR genotype | |||||
|---|---|---|---|---|---|
| Total | TT | CT | CC | p-value | |
| N = 326 | n = 37 | n = 124 | n = 165 | ||
| PANSS Psychosis Criteria Met | |||||
| no | 261 (80.0%) | 33 (89.2%) | 96 (77.4%) | 132 (80.0%) | 0.31 |
| yes | 65 (20.1%) | 4 (10.8%) | 28 (22.6%) | 33 (20.0%) | |
| RBC folate (ng/ml) | |||||
| Mean (SD) | 705.0 (238.7) | 830.4 (369.8) | 698.9 (206.9) | 681.4(216.1) | 0.002 |
| Taking a Folic Acid Supplement (n = 324) | |||||
| no | 71 (21.9%) | 6 (16.7%) | 24 (19.4%) | 42 (25.6%) | 0.42 |
| yes* | 253 (78.1%) | 30 (83.3%) | 100 (80.6%) | 122 (73.9%) | |
| Taking a daily psychotropic medication (n = 324) | |||||
| no | 244 (75.3%) | 28 (75.7%) | 95 (77.2%) | 121 (73.8%) | 0.82 |
| yes | 80 (24.7%) | 9 (24.3%) | 28 (22.6%) | 43 (26.2%) | |
* n = 1 participant took 5-MTHF supplements (not folic acid).